Flow Cytometry currently has broad applications in R&D as well as drug-design. The sensitivity and analytical capabilities of the modern Flow Cytometry systems combined with FlowMetric Diagnostics Inc. proprietary methods will play a central role in its development of novel and innovative diagnostics.
"This new affiliate company," says Ren Capocasale, FlowMetric CEO, "represents the natural progression of the FlowMetric, Inc. business into the clinical marketplace and recognizes the need for additional diagnostics."
FlowMetric Diagnostics leadership will include Amy Williams as President and Julie Bick, Ph.D. as Chief Scientific Officer. Ren Capocasale will operate as Chairman of the Board.
"The development of new companion diagnostics through flow cytometry can help to advance personalized medicine and better meet the needs of physicians, healthcare workers and patients," said Williams.
FlowMetric Diagnostics Inc. plans to establish a state-of-the-art FDA-compliant clinical Flow Cytometry laboratory in which to perform CLIA-certified diagnostic tests from both the company's own assay portfolio, as well as those of partnering diagnostic companies.
FlowMetric, Inc., is a niche contract research organization (CRO), focused on providing polychromatic flow cytometry and cell sorting services to bio-pharma and drug discovery companies. FlowMetric is committed to providing independent, unbiased, comprehensive and precise test services as part of the pre-clinical and clinical trial process for its clients. FlowMetric offers integrated, cost-effective, and specialized polychromatic flow cytometry services delivered with an uncompromising commitment to quality. For more information, visit www.flowmetric.comand www.flowmetricdiagnostics.com.